EndoPredict versus uPA/PAI-1 in breast cancer: Comparison of markers and association with clinicopathological parameters.

Biomarkers, Tumor / analysis Breast Neoplasms / drug therapy Chemotherapy, Adjuvant Female Gene Expression Regulation, Neoplastic Humans Middle Aged Plasminogen Activator Inhibitor 1 / analysis Retrospective Studies Urokinase-Type Plasminogen Activator / analysis
breast cancer prognosis proteases

Journal

The breast journal
ISSN: 1524-4741
Titre abrégé: Breast J
Pays: United States
ID NLM: 9505539

Informations de publication

Date de publication:
05 2019
Historique:
received: 12 08 2018
revised: 16 08 2018
accepted: 22 08 2018
pubmed: 20 4 2019
medline: 27 12 2019
entrez: 20 4 2019
Statut: ppublish

Résumé

We retrospectively investigated concordance of EndoPredict (EPclin) with urokinase plasminogen activator and plasminogen activator inhibitor-1 (uPA/PAI-1) in 72 breast cancer patients and compared the results with grading, molecular subtype and chemotherapy recommendation. Compared to uPA/PAI-1, EPclin proved to be more conservative concerning correlation with clinicopathological parameters and was significantly associated with the recommendation of adjuvant chemotherapy.

Identifiants

DOI: 10.1111/tbj.13258 PMID: 31001905
pubmed: 31001905
doi: 10.1111/tbj.13258
doi:

Substances chimiques

Biomarkers, Tumor 0
Plasminogen Activator Inhibitor 1 0
SERPINE1 protein, human 0
Urokinase-Type Plasminogen Activator EC 3.4.21.73

Types de publication

Comparative Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

450-454

Informations de copyright

© 2019 Wiley Periodicals, Inc.

Auteurs

Elżbieta Jakubowicz (E)

Institute of Pathology, Universitätsklinikum Augsburg, Augsburg, Germany.
ORCID: 0000-0002-1757-9210

Benedikt Martin (B)

Institute of Pathology, Universitätsklinikum Augsburg, Augsburg, Germany.

Reinhard Hoffmann (R)

Institute of Laboratory Medicine and Microbiology, Universitätsklinikum Augsburg, Augsburg, Germany.

Thomas Kröncke (T)

Department of Diagnostic and Interventional Radiology, Universitätsklinikum Augsburg, Augsburg, Germany.

Thomas Jung (T)

Clinic for Gynecology and Obstetrics, Universitätsklinikum Augsburg, Augsburg, Germany.

Roman Steierl (R)

Frauenklinik im Josefinum Augsburg, Katholische Jugendfürsorge Fachklinik, Augsburg, Germany.

Dieter Steinfeld (D)

Gynecology Diakonissenkrankenhaus, Augsburg, Germany.

Gerhard Schenkirsch (G)

Tumor Data Management, Interdisciplinary Cancer Center Augsburg, Augsburg, Germany.

Jörg Kriegsmann (J)

Histology, Cytology and Molecular Diagnostics Center Trier, Trier, Germany.

Bruno Märkl (B)

Institute of Pathology, Universitätsklinikum Augsburg, Augsburg, Germany.
ORCID: 0000-0002-7704-850X

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Facteurs biologiques › Marqueurs biologiques › Marqueurs biologiques tumoraux › EndoPredict versus uPA/PAI-1 in breast cancer:...
questionsmedicales.fr › Maladies de la peau et du tissu conjonctif › Maladies de la peau › Maladies du sein › Tumeurs du sein › EndoPredict versus uPA/PAI-1 in breast cancer:...
questionsmedicales.fr › Thérapeutique › Traitement médicamenteux › Traitement médicamenteux adjuvant › EndoPredict versus uPA/PAI-1 in breast cancer:...
questionsmedicales.fr › Phénomènes génétiques › Régulation de l'expression des gènes › Régulation de l'expression des gènes tumoraux › EndoPredict versus uPA/PAI-1 in breast cancer:...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › EndoPredict versus uPA/PAI-1 in breast cancer:...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Adulte d'âge moyen › EndoPredict versus uPA/PAI-1 in breast cancer:...
questionsmedicales.fr › Facteurs biologiques › Facteurs de la coagulation sanguine › Inhibiteurs d'activateurs du plasminogène › Inhibiteur-1 d'activateur du plasminogène › EndoPredict versus uPA/PAI-1 in breast cancer:...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études de cohortes › Études rétrospectives › EndoPredict versus uPA/PAI-1 in breast cancer:...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines du sang › Activateurs du plasminogène › Activateur du plasminogène de type urokinase › EndoPredict versus uPA/PAI-1 in breast cancer:...